Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

zipjet

Send PM Follow Ignore
Followers 36
Posts 2637
Boards Moderated 0
Alias Born 10/06/2003

zipjet

Re: DewDiligence post# 101952

Thursday, 08/19/2010 7:23:04 PM

Thursday, August 19, 2010 7:23:04 PM

Post# of 257580

Robyn Karnauskas of Deutsche Bank forecasts that US Tysabri sales will fall from $633M in 2010 to $376M in 2015 as newer and safer MS drugs reach the market.



I'm all in for safer, IF EFFECTIVE, MS treatments. (My wife is on Tysabri after failing Copaxone.)

BUT what I am hearing is that Gilenia carries a cancer risk. Weighing a quantifiable PML risk against an unquantifiable cancer risk versus the ravages of MS is awful.

ij

There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today